# Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

> **NCT02436759** · PHASE3 · COMPLETED · sponsor: **RVL Pharmaceuticals, Inc.** · enrollment: 140 (actual)

## Conditions studied

- Acquired Blepharoptosis

## Interventions

- **DRUG:** RVL-1201
- **DRUG:** RVL-1201 Vehicle Placebo

## Key facts

- **NCT ID:** NCT02436759
- **Lead sponsor:** RVL Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2021-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02436759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02436759, "Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02436759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*